首頁 > 市場調查報告書 > 製藥

生物標記循環系統

市場調查報告書

商品編碼

1746599

日本心臟生物標記市場報告（按類型（肌鈣蛋白、心肌肌酸激酶、肌紅蛋白、腦鈉肽或 NT-proBNP、缺血修飾白蛋白等）、檢測地點、應用和地區）2025 年至 2033 年

Japan Cardiac Biomarkers Market Report by Type (Troponins, Myocardial Muscle Creatine Kinase, Myoglobin, Brain Natriuretic Peptide or NT-proBNP, Ischemia Modified Albumin, and Others), Location of Testing, Application, and Region 2025-2033

出版日期: 2025年06月02日 | 出版商:

IMARC | 英文 120 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2024年，日本心臟生物標記市場規模達6.801億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到13.027億美元，2025-2033年期間的複合年成長率（CAGR）為7.5%。心臟病發作、中風和心臟衰竭等心血管疾病的發生率不斷上升，這些疾病需要利用心臟生物標記進行早期檢測、風險評估和患者監測，從而推動市場發展。

心臟生物標記是心臟相關疾病發生時釋放到血液中的蛋白質或分子。它們在診斷和監測各種心臟疾病中發揮著至關重要的作用。常見的心臟生物標記包括肌鈣蛋白、肌酸激酶同工酶 (CK-MB) 和 B 型利鈉肽 (BNP)。肌鈣蛋白是心肌損傷的高度特異性指標，在診斷心臟病發作中至關重要。 CK-MB 是另一種因心肌損傷而升高的酵素。而 BNP 則有助於評估心臟衰竭及其嚴重程度。透過血液檢測測量心臟生物標記物，醫療保健專業人員可以檢測和評估心臟問題，確定損傷程度，並制定合適的治療方案。這些生物標記為心臟整體健康狀況提供了寶貴的見解，並有助於指導醫療干預措施以改善患者預後。定期監測心臟生物標記對於管理心臟疾病和預防併發症至關重要。

日本心臟生物標記市場趨勢：

日本的心臟生物標記市場預計將大幅成長，這主要得益於以下幾個關鍵因素。首先，心血管疾病（包括冠狀動脈疾病和心臟衰竭）的盛行率不斷上升，顯著增加了對心臟生物標記檢測的需求。此外，該地區人口老化也是一個主要促進因素，因為老年人患心臟相關疾病的風險更高，從而對心臟生物標記診斷的需求持續成長。此外，醫療技術的進步和高靈敏度心臟生物標記檢測的日益普及，提高了心臟疾病檢測的準確性和效率。這不僅改善了患者的預後，也鼓勵醫療保健提供者將這些檢測納入其常規臨床實踐。此外，醫療保健專業人員和患者對早期發現和預防心臟疾病重要性的認知不斷提高，也導致了檢測率的提高。對預防性醫療保健和主動監測心臟健康的重視，促進了心臟生物標記市場的發展。最後，政府的支持性措施以及對心血管研究和診斷工具的資助，也推動了市場擴張。總體而言，這些促進因素共同為心臟生物標記市場在可預見的未來持續成長創造了有利的前景。

日本心臟生物標記市場細分：

類型洞察：

肌鈣蛋白（T 和 I）
心肌肌酸激酶（CK-MB）
肌紅蛋白
腦鈉肽 (BNPs) 或 NT-proBNP
缺血修飾白蛋白（IMA）
其他

測試洞察的位置：

實驗室測試
即時檢驗

應用程式洞察：

心肌梗塞
充血性心臟衰竭
急性冠狀動脈綜合症
動脈粥狀硬化
其他

競爭格局：

市場研究報告也對競爭格局進行了全面的分析。報告涵蓋了市場結構、關鍵參與者定位、最佳制勝策略、競爭儀錶板和公司評估象限等競爭分析。此外，報告還提供了所有主要公司的詳細資料。

本報告回答的關鍵問題：

日本心臟生物標記市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本心臟生物標記市場有何影響？
日本心臟生物標記市場依類型分為哪些類型？
根據檢測地點，日本心臟生物標記市場是如何分類的？
根據應用情況，日本心臟生物標記市場是如何分類的？
日本心臟生物標記市場的價值鏈分為哪些階段？
日本心臟生物標記的主要促進因素和挑戰是什麼？
日本心臟生物標記市場的結構是怎麼樣的？主要參與者是誰？
日本心臟生物標記市場的競爭程度如何？

本報告回答的關鍵問題：

日本心臟生物標記市場迄今表現如何？未來幾年將如何表現？
COVID-19 對日本心臟生物標記市場有何影響？
日本心臟生物標記市場依類型分為哪些類型？
根據檢測地點，日本心臟生物標記市場是如何分類的？
根據應用情況，日本心臟生物標記市場是如何分類的？
日本心臟生物標記市場的價值鏈分為哪些階段？
日本心臟生物標記的主要促進因素和挑戰是什麼？
日本心臟生物標記市場的結構是怎麼樣的？主要參與者是誰？
日本心臟生物標記市場的競爭程度如何？

Japan cardiac biomarkers market size reached USD 680.1 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,302.7 Million by 2033, exhibiting a growth rate (CAGR) of 7.5% during 2025-2033. The increasing prevalence of cardiovascular diseases such as heart attacks, strokes, and heart failure, that require cardiac biomarkers for early detection, risk assessment, and monitoring of patients, is driving the market.

Cardiac biomarkers are proteins or molecules released into the bloodstream in response to heart-related conditions. They play a crucial role in diagnosing and monitoring various heart disorders. Common cardiac biomarkers include troponins, creatine kinase-MB (CK-MB), and B-type natriuretic peptide (BNP). Troponins are highly specific indicators of heart muscle damage and are essential in diagnosing heart attacks. CK-MB is another enzyme that rises in response to heart muscle injury. BNP, on the other hand, helps assess heart failure and its severity. Measuring cardiac biomarkers through blood tests allows healthcare professionals to detect and evaluate heart problems, determine the extent of damage, and formulate appropriate treatment plans. These biomarkers provide valuable insights into the overall health of the heart and help guide medical interventions to improve patient outcomes. Regular monitoring of cardiac biomarkers is essential in managing heart conditions and preventing complications.

Japan Cardiac Biomarkers Market Trends:

The cardiac biomarkers market in Japan is poised for substantial growth, driven by several key factors. Firstly, the escalating prevalence of cardiovascular diseases, including coronary artery disease and heart failure, has significantly increased the demand for cardiac biomarker testing. Additionally, the aging regional population is a major driver, as older individuals are at higher risk of cardiac-related issues, creating a sustained need for cardiac biomarker diagnostics. Moreover, advancements in medical technology and the increasing adoption of high-sensitivity cardiac biomarker assays have enhanced the accuracy and efficiency of cardiac disease detection. This has not only improved patient outcomes but also encouraged healthcare providers to incorporate these tests into their routine clinical practices. Furthermore, the growing awareness among both healthcare professionals and patients regarding the importance of early cardiac disease detection and prevention has led to increased testing rates. The emphasis on preventive healthcare and proactive monitoring of cardiac health has bolstered the cardiac biomarkers market. Lastly, supportive government initiatives and funding for cardiovascular research and diagnostic tools have fueled market expansion. Overall, these drivers converge to create a favorable landscape for the cardiac biomarkers market's sustained growth in the foreseeable future.

Japan Cardiac Biomarkers Market Segmentation:

Type Insights:

Troponins (T and I)
Myocardial Muscle Creatine Kinase (CK-MB)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia Modified Albumin (IMA)
Others

Location of Testing Insights:

Laboratory Testing
Point of Care Testing

Application Insights:

Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan cardiac biomarkers market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan cardiac biomarkers market?
What is the breakup of the Japan cardiac biomarkers market on the basis of type?
What is the breakup of the Japan cardiac biomarkers market on the basis of location of testing?
What is the breakup of the Japan cardiac biomarkers market on the basis of application?
What are the various stages in the value chain of the Japan cardiac biomarkers market?
What are the key driving factors and challenges in the Japan cardiac biomarkers?
What is the structure of the Japan cardiac biomarkers market and who are the key players?
What is the degree of competition in the Japan cardiac biomarkers market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cardiac Biomarkers Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Cardiac Biomarkers Market Landscape

5.1 Historical and Current Market Trends (2019-2024)
5.2 Market Forecast (2025-2033)

6 Japan Cardiac Biomarkers Market - Breakup by Type

6.1 Troponins (T and I)
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
6.2 Myocardial Muscle Creatine Kinase (CK-MB)
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
6.3 Myoglobin
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
6.4 Brain Natriuretic Peptide (BNPs) or NT-proBNP
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
6.5 Ischemia Modified Albumin (IMA)
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2019-2024)
- 6.5.3 Market Forecast (2025-2033)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2019-2024)
- 6.6.2 Market Forecast (2025-2033)

7 Japan Cardiac Biomarkers Market - Breakup by Location of Testing

7.1 Laboratory Testing
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
7.2 Point of Care Testing
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)

8 Japan Cardiac Biomarkers Market - Breakup by Application

8.1 Myocardial Infarction
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
8.2 Congestive Heart Failure
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
8.3 Acute Coronary Syndrome
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
8.4 Atherosclerosis
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
8.5 Others
- 8.5.1 Historical and Current Market Trends (2019-2024)
- 8.5.2 Market Forecast (2025-2033)

9 Japan Cardiac Biomarkers Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Services Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Services Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Services Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Services Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Services Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Cardiac Biomarkers Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis